MNA-001
Asset
Activates TREM2 to enhance microglial function, resolve misfolded protein pathology, and protect neurons from degeneration.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- TREM2
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Alzheimer's disease
Phase 1, munatherapeutics.com, 7 Oct 2026
Early-stage Alzheimer's disease
Phase 1, munatherapeutics.com, 10 Oct 2026
In the full profile
- Targets and what it contains4
- Owner and partners1
- Evidence for its targets5
- Competitors12
- Aging relevance2
Every asset’s record: target, stage, trials and the evidence behind it.